scholarly journals Neuropathic pain treatment between drug therapy and supplement effects

2019 ◽  
Vol 8 (11) ◽  
pp. 2573
Author(s):  
Mohammed Abdul Muttalib
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment ◽  
Medical Condition ◽  
Medical Procedure ◽  
Over The Counter ◽  
Cell Systems ◽  
Serious Illness ◽  
Topical Lidocaine ◽  
Somatosensory Nervous System ◽  
Strong Medicine

Neuropathic pain (NP) is a medical condition induced by diseases or lesions in the primary or inner cell systems that influence somatosensory nervous system buildings. Central NP, including backbone pain; multiple sclerosis, is recurrent. NP has an important impact on the life of patients and a strong economic impact on people and the society. some small neuropathy responds like a NSAID, aspirin and ibuprofen to an over-the-counter drug. More strong medicine (such as anti-depressants and serotonin-epinephrine reuptake inhibitors), anticonvulsants (pregabalin and gabapentin), and topical lidocaine-these are recognized as the most advanced neuropathical treatment-is also needed for other serious circumstances to increase ache leadership. Supplemental drugs, such as beta lipoic acid, acetyl-L-carnitine, benfotiamine, taurine and others, have been studied for neuropathic pain relieve under doctors to guarantee safe use and not bring any medicines that may interact with the dietary supplement. A medical procedure has been investigated for a neuro-lipoic pain relief. In specific, owing to the power of drug contrast with alternative products and owing to the effect of some drugs, it was considered that the drugs are (in spite of their side effects) more helpful and efficient to relieve neuropathic pain than the option, since neuropathic pain represents a serious illness and needs a more strong and effective therapy technology (particularly in severe cases).

scholarly journals Food-Derived Natural Compounds for Pain Relief in Neuropathic Pain

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Eun Yeong Lim ◽  
Yun Tai Kim
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Immune Responses ◽  
Pain Treatment ◽  
Physical Dependence ◽  
Natural Compounds ◽  
Number Of Patients ◽  
Potential Benefits ◽  
Somatosensory Nervous System ◽  
Injury Causes

Neuropathic pain, defined as pain caused by a lesion or disease of the somatosensory nervous system, is characterized by dysesthesia, hyperalgesia, and allodynia. The number of patients with this type of pain has increased rapidly in recent years. Yet, available neuropathic pain medicines have undesired side effects, such as tolerance and physical dependence, and do not fully alleviate the pain. The mechanisms of neuropathic pain are still not fully understood. Injury causes inflammation and immune responses and changed expression and activity of receptors and ion channels in peripheral nerve terminals. Additionally, neuroinflammation is a known factor in the development and maintenance of neuropathic pain. During neuropathic pain development, the C-C motif chemokine receptor 2 (CCR2) acts as an important signaling mediator. Traditional plant treatments have been used throughout the world for treating diseases. We and others have identified food-derived compounds that alleviate neuropathic pain. Here, we review the natural compounds for neuropathic pain relief, their mechanisms of action, and the potential benefits of natural compounds with antagonistic effects on GPCRs, especially those containing CCR2, for neuropathic pain treatment.

Management issues in neuropathic pain

2015 ◽  
Author(s):  
Nanna Brix Finnerup ◽  
Troels Staehelin Jensen
Keyword(s):  
Nervous System ◽  
Neuropathic Pain ◽  
Cancer Survivors ◽  
Tricyclic Antidepressants ◽  
Topical Lidocaine ◽  
Noradrenaline Reuptake ◽  
Somatosensory Nervous System ◽  
Disease Free ◽  
Management Issues

Neuropathic pain is a common complication to cancer, cancer treatment, HIV, and other conditions that may affect the somatosensory nervous system. Neuropathic pain may be present in up to 40% of cancer patients and may persist independently of the cancer and affect the quality of life in disease-free cancer survivors. Particular surgical treatment and chemotherapy may cause chronic persistent neuropathic pain in cancer survivors. The diagnosis of neuropathic pain can be challenging and requires documentation of a nervous system lesion and pain in areas of sensory changes. The pharmacological treatment may include tricyclic antidepressants, selective serotonin noradrenaline reuptake inhibitors (duloxetine or venlafaxine), calcium channel α2↓ agonists (gabapentin or pregabalin), and opioids. Topical lidocaine and capsaicin, NMDA antagonists, carbamazepine, oxcarbazepine, and cannabinoids may be indicated. Due to limited efficacy or intolerable side effects at maximal doses, combination therapy is often required and careful monitoring of effect and adverse reactions is important.

scholarly journals Neuropathic Pain and Rehabilitation: A Systematic Review of International Guidelines

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 74
Author(s):  
Andrea Bernetti ◽  
Francesco Agostini ◽  
Alessandro de Sire ◽  
Massimiliano Mangone ◽  
Lucrezia Tognolo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Neuropathic Pain ◽  
English Language ◽  
Pain Treatment ◽  
Rehabilitation Program ◽  
Pharmacological Intervention ◽  
Rehabilitative Treatment ◽  
Relevant Role ◽  
Rehabilitative Intervention ◽  
Somatosensory Nervous System

Background: Neuropathic pain is an injury or disease of the central and/or peripheral somatosensory nervous system, and it has a significant impact on quality of life, especially since it is often refractory to treatment. Rehabilitative intervention is considered in various guidelines on neuropathic pain treatment, although not in an organic nor detailed way. The aim of this systematic review was to analyze the most indicated therapeutic strategies, providing rehabilitative recommendations in the management of neuropathic pain. Methods: A systematic review was performed according to PRISMA guidelines. The scientific search, carried out until July 2020, considered guidelines in English language of the last thirteen years. Results: Six guidelines were analyzed, from which emerges that a multidisciplinary approach, comprehensive of pharmacologic and nonpharmacologic interventions, should drive neuropathic pain management. A relevant role in non-pharmacological intervention is played by rehabilitation, through an adequate tailored rehabilitation program and physical therapies. Conclusion: This analysis highlights the importance of rehabilitation but also the lack of evidence on various rehabilitative practices. Arises hence the need for further studies in this field to better define a rehabilitative treatment strategy.

Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands

2015 ◽  
Vol 21 (13) ◽  
pp. 1723-1740 ◽  
Author(s):  
Katarzyna Panczyk ◽  
Sylwia Go.lda ◽  
Anna Waszkielewicz ◽  
Dorota Zelaszczyk ◽  
Agnieszka Gunia-Krzyz.ak ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment ◽  
Serotonergic System ◽  
Receptor Ligands

scholarly journals Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights Into the Clinical Challenges of Pain Treatment?

2021 ◽  
Vol 2 ◽  
Author(s):  
Isaura Tavares ◽  
José Tiago Costa-Pereira ◽  
Isabel Martins
Keyword(s):  
Neuropathic Pain ◽  
Pain Control ◽  
Pain Treatment ◽  
Reticular Nucleus ◽  
Serotoninergic System ◽  
High Plasticity ◽  
Descending Facilitation ◽  
Pain Models ◽  
Dual Action ◽  
Control Circuits

The treatment of neuropathic pain remains a clinical challenge. Analgesic drugs and antidepressants are frequently ineffective, and opioids may induce side effects, including hyperalgesia. Recent results on brainstem pain modulatory circuits may explain those clinical challenges. The dual action of noradrenergic (NA) modulation was demonstrated in animal models of neuropathic pain. Besides the well-established antinociception due to spinal effects, the NA system may induce pronociception by directly acting on brainstem pain modulatory circuits, namely, at the locus coeruleus (LC) and medullary dorsal reticular nucleus (DRt). The serotoninergic system also has a dual action depending on the targeted spinal receptor, with an exacerbated activity of the excitatory 5-hydroxytryptamine 3 (5-HT3) receptors in neuropathic pain models. Opioids are involved in the modulation of descending modulatory circuits. During neuropathic pain, the opioidergic modulation of brainstem pain control areas is altered, with the release of enhanced local opioids along with reduced expression and desensitization of μ-opioid receptors (MOR). In the DRt, the installation of neuropathic pain increases the levels of enkephalins (ENKs) and induces desensitization of MOR, which may enhance descending facilitation (DF) from the DRt and impact the efficacy of exogenous opioids. On the whole, the data discussed in this review indicate the high plasticity of brainstem pain control circuits involving monoaminergic and opioidergic control. The data from studies of these neurochemical systems in neuropathic models indicate the importance of designing drugs that target multiple neurochemical systems, namely, maximizing the antinociceptive effects of antidepressants that inhibit the reuptake of serotonin and noradrenaline and preventing desensitization and tolerance of MOR at the brainstem.

scholarly journals Neuropathic pain treatment: still a challenge

2016 ◽  
Vol 8 (2) ◽  
Author(s):  
Osvaldo J.M. Nascimento ◽  
Bruno L. Pessoa ◽  
Marco Orsini ◽  
Pedro Ribeiro ◽  
Eduardo Davidovich ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pain Control ◽  
Pain Treatment ◽  
Botulinum Toxin Type A ◽  
Somatosensory System ◽  
Botulinum Toxin Type ◽  
Controlled Trials ◽  
Channel Blockers ◽  
Voltage Gated ◽  
Randomized Controlled

Neuropathic pain (NP) is the result of a series of conditions caused by diseases or lesions to the somatosensory system. Due to the better understanding of NP pathophysiology previously unexplored therapies have been used with encouraging results. In this group, acetyl-L-carnitine, alpha-lipoic-acid, cannabinoids, clonidine, EMA401, botulinum toxin type A and new voltage-gated sodium channel blockers, can be included. Besides, changing paradigms may occur with the advent of optogenetics and a better understanding of epigenetic regulation. We reviewed the published literature on the pharmacological treatment of NP. Despite the interesting results, randomized controlled trials are demanded the majority of the therapies previously mentioned. In spite of several studies for the relief of NP, pain control continues being a challenge.

Neuropathic pain treatment: a further step forward

The Lancet ◽  
2009 ◽  
Vol 374 (9697) ◽  
pp. 1218-1219 ◽  
Author(s):  
Troels Staehelin Jensen ◽  
Nanna Brix Finnerup
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment
Sign in / Sign up

Export Citation Format

Share Document